Shire’s Prucalopride Brings Real-World CV Safety Data To US FDA Panel, But Will It Be Enough?

European postmarketing epidemiological study results ‘reasonably exclude’ a greater than three-fold increased risk of major adverse cardiovascular events with the constipation drug but, due to potential bias, cannot definitively exclude a possibly unacceptable level of risk, agency says.

3d render illustration of human digestive system - front view

The US FDA is asking its Gastrointestinal Drugs Advisory Committee whether the results from short-term clinical trials and a European postmarketing observational study, which was submitted in lieu of a premarketing safety study, are adequate to characterize the cardiovascular safety of Shire PLC’s Motegrity (prucalopride) for chronic idiopathic constipation.

In briefing documents released ahead of the Oct. 18 committee meeting, FDA suggests that while Shire has demonstrated efficacy for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers